email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
1606 - 1620
of 3612 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
Next
Gracell Closes $100 Million C Funding for Novel CAR-T Technologies
$5.00
Available
Citrine to Bring Treatment for Narcolepsy, a Rare Disease, to China
$5.00
Available
Aprinoia to Start China Trial of PET Tracing Agent for Alzheimer's
$5.00
Available
CStone Out-licenses Ex-China Rights for Two Immunotherapies in $1.3 Billion Agreement
$5.00
Available
CASI Enters $95 Million China Deal for BioInvent's Checkpoint Inhibitor
$5.00
Available
Reistone Reports Successful Test of JAK1 Inhibitor for Atopic Dermatitis
$5.00
Available
Gmax of Hangzhou Starts China-US Trials of Antibody Drug for PAH
$5.00
Available
Siranomics Closes $105 Million Funding from China Investors; Plans IPO
$5.00
Available
Gland Pharma, Fosun's Indian Subsidiary, Approved for $814 Million IPO
$5.00
Available
Ascentage Granted China Priority Review of NDA for BCR-ABL Inhibitor
$5.00
Available
Zhaoke Acquires China Rights to Myopia Treatment in $102 Million Agreement
$5.00
Available
Beijing Immunochina Raises $15 Million for CAR-T Portfolio
$5.00
Available
3DMed Completes $225 Million Round for Immunotherapy Candidates
$5.00
Available
Huadong Med Acquires ADC for Ovarian Cancer in $305 Million Agreement
$5.00
Available
Aslan Pharma Repurposes DHODH Inhibitor for Autoimmune, COVID-19 Indications
$5.00
Available